Moreover, extensive clinic research and the development of highly sensitive and specific methods to assess myelin oligodendrocyte glycoprotein antibody (MOG-Ab) disease allowed the diagnosis of a group of patients with MOG antibodies, which are also clinically and phenotypically different from MS or NMO. The gene discussed is OMG; the disease is myeloid sarcoma.